Juan Carlos Bucobo

Juan Carlos Bucobo

Auto-generated profile, based on publicly available information

Juan Carlos Bucobo

Of Medicine, Stony Brook University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
PDF file
JBJonathan M. Buscaglia
Jonathan M. Buscaglia
JBJuan Carlos Bucobo
Juan Carlos Bucobo
HTHerve Tiriac
Herve Tiriac
DTDemetrios Tzimas
Demetrios Tzimas
SGSuman Grewal
Suman Grewal
DTDavid A. Tuveson
David A. Tuveson

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
RARashmi Advani
Rashmi Advani
GVGagan Verma
Gagan Verma
KGKunal Gada
Kunal Gada
SCSunil Chulani
Sunil Chulani
SASahar Ahmad
Sahar Ahmad
JBJuan Carlos Bucobo
Juan Carlos Bucobo

15 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
RRRuben Jesus Faustino Ramos
Ruben Jesus Faustino Ramos
CZChencan Zhu
Chencan Zhu
DJDimitri F Joseph
Dimitri F Joseph
STShubh D Thaker
Shubh D Thaker
JLJoseph LaComb
Joseph LaComb
ELEllen Li
Ellen Li
Background: Fecal microbiota transplantation (FMT) is an effective treatment of recurrent Clostridioides difficile infections (rCDI). In comparison, FMT has more limited efficacy in treating either ulcerative colitis (UC) or Crohn’s disease (CD), two major forms of inflammatory bowel diseases (IBD). We hypothesize that FMT recipients with rCDI and/or IBD have baseline fecal bile acid (BA) compositions that differ significantly from that of their healthy donors and may be normalized by FMT. Aim: To study the effect of single colonoscopic FMT on the microbial composition and function of recipients with rCDI and/or IBD. Methods: Multi-omic analysis was performed on stools from 55 pairs of subjects and donors enrolled in two prospective single arm FMT clinical trials [ ClinicalTrials.gov ID: NCT03268213 , 479696, (IND) 15642, ClinicalTrials.gov ID: NCT03267238 , IND 16795]. Fitted linear mixed models were used to examine the effects of four recipient groups (rCDI - IBD, rCDI + IBD, UC - rCDI, CD - rCDI), FMT status (Donor, pre-FMT, 1-week post-FMT, 3-months post-FMT) and first order Group*FMT interactions. Results: FMT was effective in preventing rCDI for up to one year in 92% of the rCDI - IBD group and 75% of the rCDI + IBD recipients. The donor-recipient Sørensen similarity index was < 0.6 in all donor-CDI recipient pairs but > 0.6 in some donor-IBD only recipient pairs at baseline. Increasing post-FMT similarity indices > 0.6 in IBD recipients, was not clearly associated with reduced fecal calprotectin levels. Fecal secondary BA levels were lower in rCDI ± IBD and CD – rCDI recipients compared to donors. FMT restored secondary BA levels in these recipients. Metagenomic baiE gene and some of the 8 bile salt hydrolase (BSH) phylotype abundances were significantly correlated with fecal BA levels. Conclusion: Restoration of multiple secondary BA levels, including those recently implicated in immunomodulation, are associated with restoration of fecal baiE gene counts, suggesting that the 7-α-dehydroxylation step is rate-limiting.